FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark, Zhou, Xin, Zhao, Gexin, Chen, Hong, Li, Xinmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216110/
https://www.ncbi.nlm.nih.gov/pubmed/34164344
http://dx.doi.org/10.3389/fonc.2021.683419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216110/
https://www.ncbi.nlm.nih.gov/pubmed/34164344
http://dx.doi.org/10.3389/fonc.2021.683419

Ejemplares similares